Wedbush maintains an 'Outperform' rating on OncoGenex Pharmaceuticals (Nasdaq: OGXI) and $56 price target, but removes stock from Best Ideas ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE